A Phase 1 interventional study of AZD2389 and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 368 studies in Liver Diseases with a site in United States — 45 open to participants now, 59 under way, 5 of them phase 3. Liver Diseases · United States.
Among the 368 studies in Liver Diseases with a site in United States, this one is the 64th largest by enrollment of the 269 interventional ones that give a count, is one of 19 that started in 2023, is one of 62 in phase 1, and was the 326th registered.
825 studies on the registry are indexed under Liver Diseases; 152 are open to participants now.
Browse Liver Diseases studies →45 of the 368 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:
West Virginia University · Sites in United States
Ages 18+
AusperBio Therapeutics Inc. · Sites in United States, Canada, France and 3 more countries
Ages 18–65
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 6–17
Incyte Corporation · Sites in United States
Ages 18–80
Henry Ford Health System · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
368 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 71 · Phase 2 75 · Phase 3 30 · Phase 4 21
First in 1988; this study’s year is marked. 19 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 52 across 521 interventional studies indexed under Liver Diseases.
Median enrollment 48 across the 269 interventional studies, 153 across the 90 observational. Of the 276 that completed or were terminated, 115 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
146 of 368 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 4 studies filed under Liver Diseases — fewer than ten, so there is no comparison to draw.
21 of the studies in Liver Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04612764Baylor College of MedicineLiver Disease in Urea Cycle Disorders | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT05953337ABK BiomedicalRadioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | 2027-02 |
| NCT05264051University of ChicagoMAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease | 2027-03-01 |
| NCT07746999Corey DeStefanoNorth Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health | 2027-03-15 |
Add all 21 to your calendar (.ics) → With an account.
Among the 368 studies in Liver Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD2389 following single and multiple dose administration (SAD/MAD) to healthy participants.
This is a Phase I, First In Human (FIH), randomized, single-blind, placebo-controlled, single and multiple ascending dose study in healthy male and/or female participants of non-childbearing potential including healthy participants of Chinese and Japanese ethnicity performed at a single center.
The study consists of 2 parts: Part A and Part B. Part A has been planned to be conducted with 78 participants and Part B has been planned to be conducted with 32 participants.
Each participant in Part A and Part B will be involved in the study for up to 8 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Drug: AZD2389 · Drug: Placebo
A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Drug: AZD2389 · Drug: Placebo
A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Drug: AZD2389 · Drug: Placebo
A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Drug: AZD2389 · Drug: Placebo
A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Drug: AZD2389 · Drug: Placebo
A total of 6 study participants will receive a single dose of AZD2389.
Drug: AZD2389
A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Drug: AZD2389 · Drug: Placebo
A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Drug: AZD2389 · Drug: Placebo
A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Drug: AZD2389 · Drug: Placebo
A total of 6 study participants will receive a single dose of AZD2389 and 2 will receive placebo.
Drug: AZD2389 · Drug: Placebo
A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
Drug: AZD2389 · Drug: Placebo
A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
Drug: AZD2389 · Drug: Placebo
A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
Drug: AZD2389 · Drug: Placebo
A total of 6 study participants will receive multiple doses of AZD2389 and 2 will receive placebo.
Drug: AZD2389 · Drug: Placebo
Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.
Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.
Part A (SAD): Number of participants with adverse events (AE) and serious adverse events (SAE)
To assess the safety and tolerability of AZD2389 following oral administration of single ascending doses in healthy participants, including Japanese and Chinese participants.
Time frame: Day ≤ -28 (Only SAE), Day -1 (Only SAE), Days 1 and 2, Day 8 Post-dose (± 1 day)
Part B (MAD): Number of participants with AE and SAE
To assess the safety and tolerability of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day ≤ -28 (Only SAE), Day -1 (Only SAE), Days 1 to 12, Day 17 (± 1 day)
Part A (SAD): Plasma concentrations of AZD2389
To characterize the plasma concentration of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Urine concentrations of AZD2389
To characterize the urine concentration of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Terminal rate constant (λz)
To characterize the λz of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]
To characterize the Ae(t1-t2) of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Area under plasma concentration time curve from zero to infinity (AUCinf)
To characterize the AUCinf of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Dose normalized AUCinf (AUCinf/D)
To characterize the AUCinf/D of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Area under concentration curve from time 0 to the last quantifiable concentration (AUClast)
To characterize the AUClast of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Dose normalized AUClast (AUClast/D)
To characterize the AUClast/D of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Apparent total body clearance of drug (CL/F)
To characterize the CL/F of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Maximum observed plasma (peak) drug concentration (Cmax)
To characterize the Cmax of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Dose normalized Cmax (Cmax/D)
To characterize the Cmax/D of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Renal clearance (CLR)
To characterize the CLR of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]
To characterize the fe(t1-t2) of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Mean residence time (MRTinf)
To characterize the MRTinf of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Apparent terminal elimination half-life (t½λz)
To characterize the t½λz of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Time of last quantifiable concentration (tlast)
To characterize the tlast of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Time to reach peak or maximum observed concentration (tmax)
To characterize the tmax of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Apparent volume of distribution based on the terminal phase (Vz/F)
To characterize the Vz/F of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part A (SAD): Change in PD biomarkers over time
To characterize the percentage change in PD biomarkers over time compared to baseline of AZD2389 after single oral dosing in healthy participants, including Japanese and Chinese participants.
Time frame: Day 1 and Day 2
Part B (MAD): Plasma concentrations of AZD2389
To characterize the plasma concentration of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Urine concentrations of AZD2389
To characterize the urine concentration of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 and Days 10 to 12
Part B (MAD): Terminal rate constant (λz)
To characterize the λz of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]
To characterize the Ae(t1-t2) of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 and Days 10 to 12
Part B (MAD): Area under concentration curve from time 0 to the last quantifiable concentration (AUClast)
To characterize the AUClast of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Area under the concentration-time curve in the dose interval (AUCtau)
To characterize the AUCtau of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Dose normalized AUCtau (AUCtau/D)
To characterize the AUCtau/D of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Dose normalized AUClast (AUClast/D)
To characterize the AUClast/D of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Apparent total body clearance of drug (CL/F)
To characterize the CL/F of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 and Days 10 to 12
Part B (MAD): Renal clearance (CLR)
To characterize the CLR of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 and Days 10 to 12
Part B (MAD): Maximum observed plasma (peak) drug concentration (Cmax)
To characterize the Cmax of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Dose normalized Cmax (Cmax/D)
To characterize the Cmax/D of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Observed lowest concentration before the next dose is administered(Ctrough)
To characterize the Ctrough of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]
To characterize the fe(t1-t2) of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 and Days 10 to 12
Part B (MAD): Accumulation ratio for AUC (Rac AUC)
To characterize the Rac AUC of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Accumulation ratio for Cmax (Rac Cmax)
To characterize the Rac Cmax of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Time to reach peak or maximum observed concentration (tmax)
To characterize the tmax of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Apparent terminal elimination half-life (t½λz)
To characterize the t½λz of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Apparent volume of distribution based on the terminal phase (Vz/F)
To characterize the Vz/F of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Day 1 to Day 12
Part B (MAD): Change in PD biomarkers over time
To characterize the percentage change in PD biomarkers over time compared to baseline of AZD2389 following oral administration of multiple ascending doses in healthy participants, including Japanese participants.
Time frame: Days 1, 2, 4, 8, and 10
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Nov 2023 to primary completion in Aug 2025, 21 months.
Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 21 months is above that.
Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD2389